Skip to main content

Biomarkers

At Ulysses Neuroscience Ltd., we integrate a unique combination of advanced preclinical and clinical biomarker technologies – all co-located in a single dedicated laboratory – with a global clinical network to accelerate the development of therapies for:

  • Neuropsychiatric diseases: Major Depressive Disorder, Schizophrenia, Anorexia Nervosa

  • Neuromuscular disorders: Charcot-Marie-Tooth Disease (CMT), Amyotrophic Lateral Sclerosis (ALS)

  • Neurodegenerative diseases: Multiple Sclerosis (MS), Alzheimer’s Disease, Parkinson’s Disease

  • Developmental & epileptic encephalopathies (DEEs): CDKL5 Deficiency Disorder, Fragile X Syndrome

Why Partner with ULYSSES?

  • All major biomarker platforms in one lab

  • Extensively validated panels + full customization

  • Cross-species back-translation (humans, rodents, dogs)

  • Large disease & control biocollection

  • Complete regulatory, operational & analytical support

Representative biomarker analyses in Major Depressive Disorder (MDD) and CDKL5 Deficiency Disorder (CDD).

Representative biomarker analyses in Major Depressive Disorder (MDD) and CDKL5 Deficiency Disorder (CDD).
Acetylated α-tubulin to total α-tubulin ratio (Acet-Tub/ Tot-Tub) in orbitofrontal cortex tissue (left) and plasma from MDD patients versus controls (right). Plasma levels of NfL (left) and IL-10 (right) in CDD patients versus controls, with significant elevations in CDD. Data are presented as mean ± SEM; n = 12 – 34.

Validated & Customisable Endpoints

We offer an extensively validated panel of biomarkers, with the flexibility to design customised protocols to meet each client’s needs.

Representative analysis of inflammatory biomarkers in matched plasma and CSF samples from healthy volunteers. Quantification performed using U-Plex MSD plates. Data are presented as mean ± SEM; n = 4 per matrix.

Representative analysis of neurological biomarkers in matched plasma and CSF samples from healthy volunteers. Quantification performed using S-Plex MSD plates. Data shown as mean ± SEM; n = 4 per matrix.

Representative analysis of neurological biomarkers in Wistar Han (WH) and Wistar Kyoto (WKY) rats treated with Fluoxetine (10 mg/kg, SC), Desipramine (10 mg/kg, SC), Ketamine (5 mg/kg, SC), and Psilocybin (1 mg/kg, SC). FLX and DMI were dosed 24, 5, and 1 h pre-harvest, and KET and PSI were dosed 24 h pre-harvest. Detection was performed using the Odyssey Infrared Western Blot System. Data shown as mean ± SEM; n = 5-6 per matrix. ANOVA followed by Fisher’s LSD post-hoc test,  *p < 0.05, **p < 0.01, ***p < 0.001 vs. Wistar Han -Vehicle.

Sample Types & Species

Humans

Plasma, CSF, PBMCs, skin biopsy, post-mortem brain tissue, synaptosomes

Rodents

Plasma, CSF, PBMCs, brain tissue, synaptosomes

Dogs

Plasma, CSF, PBMCs

Representative multiplexed infrared Western blots showing acetylated α-tubulin and total α-tubulin expression in plasma samples from human, rat, and dog. Varying protein loads were analyzed for each. Detection was performed using the Odyssey Infrared Western Blot System.

Unique, Fully Integrated
Biomarker Laboratory

Our Cherrywood, Dublin facility houses key biomarker technologies under one roof, enabling unmatched consistency, streamlined workflows, and rapid data delivery:

  • Luminex 200: high-throughput multiplex immunoassays for inflammatory, metabolic, and neurodegenerative markers
  • MESO QuickPlex SQ 120MM: ultra-sensitive electrochemiluminescence multiplex assays for cytokines, neurodegeneration proteins, and phospho-proteins
  • Li-Cor Odyssey CLx: near-infrared Western blot imaging for synaptic proteins, cytoskeletal markers, and microtubule post-translational modification.

This configuration eliminates cross-site variability and allows direct translation between preclinical and clinical data.

Clinical Biomarker Study Workflow

We organise and manage the entire clinical biocollection process — from study design and patient recruitment to sample logistics, biobanking, biomarker analysis, and data reporting — ensuring complete integration and traceability at every step.

Extensive Biocollection

 

  • Healthy volunteer controls: plasma & CSF across age groups
  • Diseased populations: samples from neuropsychiatric, neuromuscular, neurodegenerative diseases and DEEs
  • Controlled -80°C storage with automated tracking
  • Additional Access to public & private biobanks for rare and specific cohorts

Global Clinical Network and
Proven Track Record

ELPIS Study

First international biomarker study in CDKL5 Deficiency Disorder (Europe, South America and expanding to other countries)

CMT Project

with San Raffaele Hospital, extended to ALS and MS biomarker studies

Collaborations

with world-leading neurology and psychiatry centres

Publications

Potential Translational Biomarker in Major Depression Disorder

American Society for Clinical Psychopharmacology 2024 – Poster

a-Tubulin Post-translational Modifications as Potential Translational Biomarkers in Major Depressive Disorder
Waninger, S., Freeburn, A., Kealy, J. & Bianchi, M.

Download Our Capabilities

Biomarker

Cell Culture

Behavioural Assays

EEG in Rodents

DMPK

DEEs in Mice

Psychedelics Research

Depression Models

Get in Touch

Partner with Ulysses Neuroscience Ltd.— your vanguard CRO and translational partner.
Let’s redefine what’s possible in neuroscience.